Summit Therapeutics plc Summit Therapeutics Plc : Holding(s) In Company
22 September 2017 - 1:00AM
UK Regulatory
TIDMSUMM
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS
1a. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are attached(ii)
: SUMMIT THERAPEUTICS PLC
1b. Please indicate if the issuer is a non-UK issuer
(please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate
box or boxes with an "X")
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)(iii) :
3. Details of person subject to the notification obligation(iv)
Name CANACCORD GENUITY GROUP INC
City and country of registered office (if applicable) VANCOUVER, CANADA
4. Full name of shareholder(s) (if different from
3.)(v)
Name DISCRETIONARY CLIENTS
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached(vi)
: 18 SEPTEMBER 2017
6. Date on which issuer notified (DD/MM/YYYY): 21 SEPTEMBER 2017
7. Total positions of person(s) subject to the notification
obligation
Total number
of voting
% of voting rights attached to shares (total of 8. % of voting rights through financial instruments Total of both in rights of
A) (total of 8.B 1 + 8.B 2) % (8.A + 8.B) issuer(vii)
Resulting situation on the date on which threshold
was crossed or reached 4.1548% N/A 4.1548% 70,316,908
Position of previous notification (if N/A N/A N/A
applicable)
8. Notified details of the resulting situation on
the date on which the threshold was crossed or reached(viii)
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible) Number of voting rights(ix) % of voting rights
Direct Indirect Direct Indirect
(Art 9 of Directive 2004/109/EC) (DTR5.1) (Art 10 of Directive 2004/109/EC) (DTR5.2.1) (Art 9 of Directive 2004/109/EC) (DTR5.1) (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BN40HZ01 2,921,500 4.1548%
SUBTOTAL 8. A 2,921,500 4.1548%
B 1: Financial Instruments according to Art. 13(1)(a)
of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial Expiration Exercise/ Number of voting rights that may be acquired if the % of voting rights
instrument date(x) Conversion Period(xi) instrument is
exercised/converted.
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect
according to Art. 13(1)(b) of Directive 2004/109/EC
(DTR5.3.1.1 (b))
Type of financial Expiration Exercise/ Conversion Physical or cash Number of voting rights % of voting rights
instrument date(x) Period (xi) settlement(xii)
SUBTOTAL 8.B.2
9. Information in relation to the person subject to
the notification obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not
controlled by any natural person or legal entity and
does not control any other undertaking(s) holding
directly or indirectly an interest in the (underlying)
issuer(xiii)
Full chain of controlled undertakings through which
the voting rights and/or the
financial instruments are effectively held starting
with the ultimate controlling natural person or legal
entity(xiv) (please add additional rows as necessary) X
% of voting rights if it equals or is higher than % of voting rights through financial instruments if Total of both if it equals or is higher than the notifiable
Name(xv) the notifiable threshold it equals or is higher than the notifiable threshold threshold
Canaccord
Genuity
Group
Inc.([1]
#_ftn1) 4.1548% 4.1548%
Canaccord
Genuity
Wealth
Group
Holdings
Limited 4.1548% 4.1548%
Canaccord
Genuity
Wealth
Group
Holdings
(Jersey)
Limited 4.1548% 4.1548%
Hargreave
Hale
Limited 4.1548% 4.1548%
[1] Each company set out in this table is ultimately
owned by Canaccord Genuity Group Inc.
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information(xvi)
This disclosable event is as a result of the acquisition
of Hargreave Hale Limited by Canaccord Genuity Group
Inc., through its wholly-owned subsidiary Canaccord
Genuity Wealth Group Holdings (Jersey) Limited.
Place of completion London
Date of completion 21 September 2017
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Summit Therapeutics plc via Globenewswire
http://www.summitplc.com/
(END) Dow Jones Newswires
September 21, 2017 11:00 ET (15:00 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2024 to May 2024
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Summit Therapeutics Plc (London Stock Exchange): 0 recent articles
More Summit Ther News Articles